ExoCoBio

ExoCoBio is a South Korea-based private biotechnology company developing stem cell-derived exosome products for regenerative medicine, immunology, and medical aesthetics. The company is best known for its exosome platform, ExoSCRT, which underpins both therapeutic programs and commercially oriented aesthetic products. Its disclosed therapeutic focus has included inflammatory and regenerative indications such as atopic dermatitis, acute kidney injury, inflammatory bowel disease, and acute respiratory distress syndrome, while its aesthetics business has helped drive commercialization. ExoCoBio has also expanded internationally through its acquisition of a majority ownership stake in U.S.-based medical aesthetics company BENEV. Overall, the company sits at the intersection of exosome therapeutics, regenerative biology, and aesthetic healthcare.